CD4+ T-cell priming

CD4+ T-cell priming refers to the process by which naive CD4+ T cells are activated by interaction with peptide-major histocompatibility complex (MHC) class II molecules on professional antigen-presenting cells, such as dendritic cells, in secondary lymphoid organs[1][4]. This process leads to the differentiation of CD4+ T cells into various effector subsets (e.g., Th1, Th2, Th17, Treg), which orchestrate immune responses by secreting cytokines, helping B lymphocytes produce antibodies, supporting cytotoxic lymphocyte function, and regulating inflammation[4]. CD4+ T-cell priming is a critical event in the induction of adaptive immunity, and its quality influences both the magnitude and character of downstream immune responses including those relevant to infection, vaccination, tumor immunity, and autoimmunity[2][3][4]. It is not itself a receptor, enzyme, or drug target, but a necessary step in adaptive immunity and a focus of immunological research and therapeutic manipulation (e.g., in vaccine design)[2][4].

Other names

T helper cell primingCD4 T-cell activationnaïve CD4+ T-cell activationT helper priming